Stockscreener 앱 받기
62.58
4.39%
2.63
시간 외 거래:
62.58
전일 마감가:
$59.95
열려 있는:
$60
하루 거래량:
321.45K
Relative Volume:
1.00
시가총액:
$2.35B
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-13.78
EPS:
-4.54
순현금흐름:
$-146.15M
1주 성능:
+4.06%
1개월 성능:
+2.76%
6개월 성능:
+3.32%
1년 성능:
+95.93%
1일 변동 폭
$59.47
$62.93
1주일 범위
$57.53
$62.93
52주 변동 폭
$27.31
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group - MarketBeat
(KROS) Proactive Strategies - Stock Traders Daily
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewswire
Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Emerald Advisers LLC Acquires Shares of 155,545 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $89.11 - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Analysts Offer Predictions for KROS FY2024 Earnings - Defense World
Assenagon Asset Management S.A. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Cantor Fitzgerald Weighs in on KROS FY2024 Earnings - Defense World
Brokers Set Expectations for KROS FY2024 Earnings - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
(KROS) Trading Signals - Stock Traders Daily
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating - Investing.com India
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Scotiabank - MarketBeat
Keros Therapeutics appoints new Chief Medical Officer - Investing.com
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire
Keros Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com UK
Keros Therapeutics, Inc. Appoints Yung H. Chyung as Chief Medical Officer, Effective as of November 1, 2024 - Marketscreener.com
Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Declines By 13.7% - MarketBeat
Objective long/short (KROS) Report - Stock Traders Daily
Renaissance Technologies LLC Invests $654,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Renaissance Technologies LLC Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Marshall Wace LLP Has $1.02 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Dimensional Fund Advisors LP Sells 3,691 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
19,832 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Squarepoint Ops LLC - Defense World
Squarepoint Ops LLC Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Point72 Asia Singapore Pte. Ltd. Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $90.63 Consensus PT from Analysts - MarketBeat
Understanding the Risks of Investing in Keros Therapeutics Inc (KROS) - Knox Daily
Keros Therapeutics completes enrollment for TROPOS trial - Investing.com India
Leerink Partners sees favorable conditions for Keros Therapeutics shares amid competitive landscape with Winrevair - Investing.com Canada
Nantahala Capital Management LLC Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Nantahala Capital Management LLC Acquires 84,810 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Point72 Asset Management L.P. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics completes enrollment for TROPOS trial By Investing.com - Investing.com South Africa
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Wells Fargo Initiates Coverage of Keros Therapeutics (KROS) with Overweight Recommendation - MSN
Point72 Asia Singapore Pte. Ltd. Purchases New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Blue Owl Capital Holdings LP Sells 15,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Fred Alger Management LLC Has $2.24 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Iron Deficiency Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Shield Therapeutics, Zeria Pharma, Keros Therapeutics - The Globe and Mail
Darwin Global Management Ltd. Boosts Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
17,540 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by Point72 DIFC Ltd - MarketBeat
Keros Therapeutics Inc [KROS] Insider GORDON CARL L sells 250,000 Shares for $250,000 - Knox Daily
Keros Therapeutics Inc (KROS)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World
Keros Therapeutics (NASDAQ:KROS) Receives New Coverage from Analysts at Guggenheim - Defense World
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Keros Therapeutics Inc 주식 (KROS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
2.02%
0.47%
자본화:
|
볼륨(24시간):